Valeant Ponders a Name Change to Try and Escape Past Reputation
- ‘We are looking at alternatives,’ CEO says at annual meeting
- Drugmaker’s shares down more than 95 percent amid criticism
Why Ackman's Valeant Trade Turned Into a Bust
This article is for subscribers only.
Valeant is ready to move on from “Valeant.”
Chief Executive Officer Joe Papa said that Valeant Pharmaceuticals International Inc. is considering a name change after a two-year stretch that has seen the company lose more than 95 percent of its value amid harsh criticism of its business practices and future prospects.